Notably, although ACE inhibitors and ARBs have been in clinical use for over 35 years as first-line therapies for hypertension, they also protect target organs, including the kidneys, brain, and heart [52], decrease mortality and morbidity in heart failure patients [52], and slow progression of chronic kidney disease [53]. The gene discussed is ACE; the disease is heart failure.